

# Yasodha Natkunam

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7092861/publications.pdf>

Version: 2024-02-01

265  
papers

12,614  
citations

34076

52  
h-index

30894

102  
g-index

276  
all docs

276  
docs citations

276  
times ranked

14811  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global Cytopathology-Hematopathology Practice Trends. American Journal of Clinical Pathology, 2022, 157, 196-201.	0.4	4
2	Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell, 2022, 185, 1025-1040.e14.	13.5	243
3	Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma. Blood Cancer Discovery, 2022, 3, 154-169.	2.6	8
4	Diagnostic Impact of Next-Generation Sequencing Panels for Lymphoproliferative Neoplasms on Small-Volume Biopsies. American Journal of Clinical Pathology, 2022, 158, 345-361.	0.4	3
5	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia, 2022, 36, 1703-1719.	3.3	1,211
6	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia, 2022, 36, 1720-1748.	3.3	1,023
7	CD47 expression patterns in thymic epithelial tumors.. Journal of Clinical Oncology, 2022, 40, 8586-8586.	0.8	0
8	FOXes at play in the lymphoma landscape. Leukemia and Lymphoma, 2021, 62, 5-7.	0.6	0
9	CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR refractory large B-cell lymphoma. Blood, 2021, 137, 2321-2325.	0.6	51
10	On the Shoulders of a Giant: Contributions of Thomas Grogan, MD to Hematopathology. Hemato, 2021, 2, 103-115.	0.2	0
11	Stage II diffuse large B-cell lymphoma treated with rituximab and chemotherapy with or without radiotherapy. Leukemia and Lymphoma, 2021, 62, 1840-1849.	0.6	1
12	Classic Hodgkin lymphoma in Guatemalan children of age less than six years: analysis of immune regulatory pathways and the tumor microenvironment. Leukemia and Lymphoma, 2021, 62, 1609-1618.	0.6	0
13	DLBCL-Morph: Morphological features computed using deep learning for an annotated digital DLBCL image set. Scientific Data, 2021, 8, 135.	2.4	11
14	Low-cost transcriptional diagnostic to accurately categorize lymphomas in low- and middle-income countries. Blood Advances, 2021, 5, 2447-2455.	2.5	13
15	Impact of initial biopsy type on the time to final diagnostic biopsy in patients with follicular lymphoma and suspected histologic transformation. Leukemia and Lymphoma, 2021, 62, 2864-2872.	0.6	4
16	Pitfalls in the Diagnosis of Nodular Lymphocyte Predominant Hodgkin Lymphoma: Variant Patterns, Borderlines and Mimics. Cancers, 2021, 13, 3021.	1.7	19
17	CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine, 2021, 27, 1419-1431.	15.2	273
18	Increased double-negative CD4 <sup>+</sup> T-cells reveal adult-onset autoimmune lymphoproliferative syndrome in a patient with IgG4-related disease. Haematologica, 2021, . .	1.7	0

#	ARTICLE	IF	CITATIONS
19	HGAL inhibits lymphoma dissemination by interacting with multiple Cytoskeletal proteins. <i>Blood Advances</i> , 2021, 5, 5072-5085.	2.5	2
20	The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. <i>Cancer Cell</i> , 2021, 39, 1422-1437.e10.	7.7	102
21	CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 753-758.	1.2	8
22	Tumor-Confirmed Follicular Lymphoma Mutations Are Detectable in Peripheral Blood Years Prior to Clinical Diagnosis. <i>Blood</i> , 2021, 138, 709-709.	0.6	1
23	CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 741-741.	0.6	4
24	Human Germinal Center-associated Lymphoma (HGAL) Is a Reliable Marker of Normal and Neoplastic Follicular Helper T Cells Including Angioimmunoblastic T-Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2021, Publish Ahead of Print, .	2.1	2
25	Genetic Subtypes of Systemic Anaplastic Large Cell Lymphoma Show Distinct Differences in PD-L1 Expression and Regulatory and Cytotoxic T Cells in the Tumor Microenvironment. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 10-16.	0.6	5
26	Elusive sentinels at the Hodgkin checkpoint. <i>Blood</i> , 2020, 136, 2841-2842.	0.6	2
27	Myeloid Cell Nuclear Differentiation Antigen (MND1) Positivity in Primary Follicles: Potential Pitfall in the Differential Diagnosis With Marginal Zone Lymphoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 384-388.	0.6	8
28	KLF1/EKLF expression in acute leukemia is correlated with chromosomal abnormalities. <i>Blood Cells, Molecules, and Diseases</i> , 2020, 83, 102434.	0.6	4
29	Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. <i>Blood</i> , 2020, 135, 2365-2374.	0.6	30
30	Extranodal NK/T-Cell Lymphomas: The Role of Natural Killer Cells and EBV in Lymphomagenesis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1501.	1.8	15
31	Role of FNA with core biopsy or cell block in patients with nodular lymphocyte-predominant Hodgkin lymphoma. <i>Cancer Cytopathology</i> , 2020, 128, 570-579.	1.4	8
32	Novel IRF8 and PD-L1 molecular aberrations in systemic EBV-positive T-cell lymphoma of childhood. <i>Human Pathology: Case Reports</i> , 2020, 19, 200356.	0.2	0
33	Is Merkel Cell Carcinoma of Lymph Node Actually Metastatic Cutaneous Merkel Cell Carcinoma?. <i>American Journal of Clinical Pathology</i> , 2020, 154, 369-380.	0.4	12
34	CD22-Directed CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of CD19-Directed CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2020, 136, 28-29.	0.6	3
35	CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering. <i>Blood</i> , 2020, 136, 53-54.	0.6	28
36	Recurrent Crebbp Mutations in Follicular Lymphoma Appear Localized to the Committed B-Cell Lineage. <i>Blood</i> , 2020, 136, 30-31.	0.6	2

#	ARTICLE	IF	CITATIONS
37	Clinicopathologic and microenvironmental analysis of primary cutaneous CD30-positive lymphoproliferative disorders: a 26-year experience from an academic medical center in Brazil. <i>Diagnostic Pathology</i> , 2019, 14, 115.	0.9	4
38	Additional considerations related to the elusive boundaries of EBV-associated T/NK-cell lymphoproliferative disorders. <i>Haematologica</i> , 2019, 104, e125-e126.	1.7	1
39	Breast implant-associated anaplastic large cell lymphoma in the post-mastectomy setting: Clinical and therapeutic implications. <i>Human Pathology: Case Reports</i> , 2019, 18, 200340.	0.2	0
40	High frequency of CD74 expression in lymphomas: implications for targeted therapy using a novel anti-CD74 drug conjugate. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 12-24.	1.3	15
41	An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 655-655.	0.6	4
42	A Clinically-Indolent Variant of Extranodal NK/T Cell Lymphoma with Unique Immunophenotypic Profile and Superior Outcome. <i>Blood</i> , 2019, 134, 5278-5278.	0.6	0
43	High Accuracy, Low-Cost Transcriptional Diagnostic to Transform Lymphoma Care in Low- and Middle-Income Countries. <i>Blood</i> , 2019, 134, 409-409.	0.6	2
44	Deep Sequencing of Viral Cell-Free DNA for Noninvasive Detection of Immunosuppression-Related Lymphoid Malignancies. <i>Blood</i> , 2019, 134, 885-885.	0.6	0
45	Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes. <i>Human Pathology</i> , 2018, 71, 91-99.	1.1	102
46	Granulysin, a novel marker for extranodal NK/T cell lymphoma, nasal type. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 749-757.	1.4	6
47	Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies. <i>Human Pathology</i> , 2018, 82, 39-45.	1.1	2
48	Immunohistochemistry for PAX7 is a useful confirmatory marker for Ewing sarcoma in decalcified bone marrow core biopsy specimens. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 765-769.	1.4	7
49	Expression of the transcription factor ZBTB46 distinguishes human histiocytic disorders of classical dendritic cell origin. <i>Modern Pathology</i> , 2018, 31, 1479-1486.	2.9	14
50	Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal?. <i>Blood</i> , 2018, 132, 1871-1878.	0.6	85
51	FOXP3-positive T-cell lymphomas in non-HTLV1 carriers include ALK-negative anaplastic large cell lymphoma: expanding the spectrum of T-cell lymphomas with regulatory phenotype. <i>Human Pathology</i> , 2018, 80, 138-144.	1.1	3
52	Lmo2 expression defines tumor cell identity during T-cell leukemogenesis. <i>EMBO Journal</i> , 2018, 37, .	3.5	32
53	Defining the elusive boundaries of chronic active Epstein-Barr virus infection. <i>Haematologica</i> , 2018, 103, 924-927.	1.7	18
54	Diagnosis of NK and cytotoxic T-cell disorders: a review. <i>Diagnostic Histopathology</i> , 2018, 24, 257-266.	0.2	1

#	ARTICLE	IF	CITATIONS
55	Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies. <i>Blood</i> , 2018, 132, 490-490.	0.6	43
56	Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 576-576.	0.6	4
57	Target Antigen Downregulation and Other Mechanisms of Failure after Axicabtagene Ciloleucel (CAR19) Therapy. <i>Blood</i> , 2018, 132, 4656-4656.	0.6	11
58	Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. <i>Haematologica</i> , 2017, 102, 1413-1423.	1.7	39
59	Unifying mechanism for different fibrotic diseases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 4757-4762.	3.3	155
60	EBV-Positive B-Cell Proliferations of Varied Malignant Potential. <i>American Journal of Clinical Pathology</i> , 2017, 147, 129-152.	0.4	84
61	Primary/Congenital Immunodeficiency. <i>American Journal of Clinical Pathology</i> , 2017, 147, 204-216.	0.4	16
62	Immunohistochemical Profile of MYC Protein in Pediatric Small Round Blue Cell Tumors. <i>Pediatric and Developmental Pathology</i> , 2017, 20, 213-223.	0.5	10
63	T- and NK-Cell Lymphomas and Systemic Lymphoproliferative Disorders and the Immunodeficiency Setting. <i>American Journal of Clinical Pathology</i> , 2017, 147, 188-203.	0.4	21
64	HHV8/KSHV-Positive Lymphoproliferative Disorders and the Spectrum of Plasmablastic and Plasma Cell Neoplasms. <i>American Journal of Clinical Pathology</i> , 2017, 147, 171-187.	0.4	74
65	B-Cell and Classical Hodgkin Lymphomas Associated With Immunodeficiency. <i>American Journal of Clinical Pathology</i> , 2017, 147, 153-170.	0.4	38
66	Epstein-Barr virus-positive follicular lymphoma. <i>Modern Pathology</i> , 2017, 30, 519-529.	2.9	44
67	KLHL6 Is Preferentially Expressed in Germinal Centerâ€Derived B-Cell Lymphomas. <i>American Journal of Clinical Pathology</i> , 2017, 148, 465-476.	0.4	7
68	Myeloid Cell Nuclear Differentiation Antigen (MND) Expression Distinguishes Extramedullary Presentations of Myeloid Leukemia From Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>American Journal of Surgical Pathology</i> , 2016, 40, 502-509.	2.1	15
69	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. <i>Journal of Clinical Oncology</i> , 2016, 34, 2690-2697.	0.8	634
70	An analysis of MYC and EBV in diffuse large B-cell lymphomas associated with angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified. <i>Human Pathology</i> , 2016, 48, 9-17.	1.1	25
71	Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma. <i>Blood</i> , 2016, 128, 239-248.	0.6	17
72	Classical Hodgkin Lymphoma with Reduced $\beta$ 2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. <i>Cancer Immunology Research</i> , 2016, 4, 910-916.	1.6	146

#	ARTICLE	IF	CITATIONS
73	Synchronous immunophenotypically and clonally distinct follicular lymphoma and marginal zone lymphoma with massive amyloid deposition. <i>Human Pathology: Case Reports</i> , 2016, 5, 10-17.	0.2	0
74	A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. <i>Leukemia and Lymphoma</i> , 2016, 57, 604-608.	0.6	12
75	Isolated Follicles Enriched for Centroblasts and Lacking t(14;18)/BCL2 in Lymphoid Tissue: Diagnostic and Clinical Implications. <i>PLoS ONE</i> , 2016, 11, e0151735.	1.1	7
76	Extracavity primary effusion lymphoma presenting in a lymph node without lymphomatous effusions. <i>Human Pathology: Case Reports</i> , 2015, 2, 36-41.	0.2	2
77	Expression Profiles of MYC Protein and MYC Gene Rearrangement in Lymphomas. <i>American Journal of Surgical Pathology</i> , 2015, 39, 294-303.	2.1	76
78	Indolent T-lymphoblastic proliferation: a name with specific meaning. <i>Human Pathology</i> , 2015, 46, 1785-1786.	1.1	6
79	Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma in the Modern Era. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 67-75.	0.4	9
80	Immunoarchitectural patterns of progressive transformation of germinal centers with and without nodular lymphocyte-predominant Hodgkin lymphoma. <i>Human Pathology</i> , 2015, 46, 1655-1661.	1.1	36
81	Large B-cell lymphoma with T-cell-rich background and nodules lacking follicular dendritic cell meshworks: description of an insufficiently recognized variant. <i>Human Pathology</i> , 2015, 46, 74-83.	1.1	8
82	Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF- $\kappa$ B pathway. <i>International Journal of Cancer</i> , 2015, 136, 2341-2351.	2.3	17
83	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. <i>Blood</i> , 2015, 126, 176-176.	0.6	4
84	Bevacizumab and cyclophosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). <i>Leukemia and Lymphoma</i> , 2014, 55, 768-772.	0.6	42
85	Hodgkin Lymphoma and the Microenvironment. , 2014, , 1701-1712.		0
86	LMO2 (LIM domain only 2) is expressed in a subset of acute myeloid leukaemia and correlates with normal karyotype. <i>Histopathology</i> , 2014, 64, 226-233.	1.6	8
87	Kappa and lambda light chain mRNA in situ hybridization compared to flow cytometry and immunohistochemistry in B cell lymphomas. <i>Diagnostic Pathology</i> , 2014, 9, 144.	0.9	21
88	Variable Expression of B-cell Transcription Factors in Reactive Immunoblastic Proliferations. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1655-1663.	2.1	12
89	Indolent T-lymphoblastic Proliferation With Disseminated Multinodal Involvement and Partial CD33 Expression. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1298-1304.	2.1	27
90	FHIT, EGFR, and MSH2. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2014, 22, 275-283.	0.6	4

#	ARTICLE	IF	CITATIONS
91	Large B-Cell Lymphomas Poor in B Cells and Rich in PD-1+ T Cells Can Mimic T-Cell Lymphomas. American Journal of Clinical Pathology, 2014, 142, 150-156.	0.4	17
92	Use of CD137 ligand expression in the detection of small B-cell lymphomas involving the bone marrow. Human Pathology, 2014, 45, 1024-1030.	1.1	8
93	Multiplexed ion beam imaging of human breast tumors. Nature Medicine, 2014, 20, 436-442.	15.2	881
94	<sc>LMO</sc>2 and <sc>BCL</sc>6 are associated with improved survival in primary central nervous system lymphoma. British Journal of Haematology, 2014, 165, 640-648.	1.2	26
95	Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte-â€Predominant Hodgkin Lymphoma. Journal of Clinical Oncology, 2014, 32, 912-918.	0.8	96
96	Myeloid cell nuclear differentiation antigen is expressed in a subset of marginal zone lymphomas and is useful in the differential diagnosis with follicular lymphoma. Human Pathology, 2014, 45, 1730-1736.	1.1	34
97	Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. Nature Communications, 2014, 5, 3904.	5.8	73
98	Programmed death receptor ligand-1 (PD-L1) expression in a thymoma (T) tissue microarray (TMA).. Journal of Clinical Oncology, 2014, 32, 7606-7606.	0.8	1
99	Clinicopathological features of aggressive B-cell lymphomas including B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell and Burkitt lymphomas: a study of 44 patients from Argentina. Annals of Diagnostic Pathology, 2013, 17, 250-255.	0.6	15
100	<i><sc>LITAF</sc></i>, a <sc>BCL</sc>6 target gene, regulates autophagy in mature B-â€cell lymphomas. British Journal of Haematology, 2013, 162, 621-630.	1.2	39
101	The spectrum of lymphoblastic, nodal and extranodal T-cell lymphomas: characteristic features and diagnostic dilemmas. Human Pathology, 2013, 44, 451-471.	1.1	10
102	Expression of the Activating Receptor, NKp46 (CD335), in Human Natural Killer and T-Cell Neoplasia. American Journal of Clinical Pathology, 2013, 140, 853-866.	0.4	36
103	Integration of Genomic Medicine into Pathology Residency Training. Journal of Molecular Diagnostics, 2013, 15, 141-148.	1.2	20
104	Follicular lymphoma in young adults: a clinicopathological and molecular study of 200 patients. Modern Pathology, 2013, 26, 1183-1196.	2.9	14
105	Indolent T-Lymphoblastic Proliferation (iT-LBP). Advances in Anatomic Pathology, 2013, 20, 137-140.	2.4	65
106	Selective Immunophenotyping for Diagnosis of B-cell Neoplasms. Applied Immunohistochemistry and Molecular Morphology, 2013, 21, 116-131.	0.6	35
107	Usefulness of HGAL and LMO2 Immunohistochemistry in the Identification of Follicular Lymphomas of the Non-Gastric Gastrointestinal Tract. Applied Immunohistochemistry and Molecular Morphology, 2013, 21, 200-204.	0.6	6
108	Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation. Nature Communications, 2013, 4, 1338.	5.8	37



#	ARTICLE	IF	CITATIONS
109	Molecular and genomic aberrations in <i>Chlamydomydia psittaci</i> negative ocular adnexal marginal zone lymphomas. American Journal of Hematology, 2013, 88, 730-735.	2.0	31
110	CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood, 2013, 122, 1233-1242.	0.6	82
111	Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood, 2013, 122, 981-987.	0.6	225
112	CD137 Ligand Is Expressed in Primary and Secondary Lymphoid Follicles and in B-cell Lymphomas. American Journal of Surgical Pathology, 2013, 37, 250-258.	2.1	10
113	Germinal Center Kinase Regulates The Proliferation and Survival Of Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 643-643.	0.6	0
114	The contribution of HGAL/GCET2 in immunohistological algorithms: a comparative study in 424 cases of nodal diffuse large B-cell lymphoma. Modern Pathology, 2012, 25, 1439-1445.	2.9	5
115	LIM domain only 2 protein expression, <i>LMO2</i> germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era. Leukemia and Lymphoma, 2012, 53, 1105-1112.	0.6	5
116	IgG4-Related Systemic Sclerosing Disease of the Ocular Adnexa. American Journal of Clinical Pathology, 2012, 137, 699-711.	0.4	40
117	TdT+ T-lymphoblastic Populations Are Increased in Castleman Disease, in Castleman Disease in Association With Follicular Dendritic Cell Tumors, and in Angioimmunoblastic T-cell Lymphoma. American Journal of Surgical Pathology, 2012, 36, 1619-1628.	2.1	73
118	Aggressive EBV-associated Lymphoproliferative Disorder. Applied Immunohistochemistry and Molecular Morphology, 2012, 20, 325-330.	0.6	4
119	Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma. Blood, 2012, 119, 5478-5491.	0.6	39
120	Cyclin D3 coordinates the cell cycle during differentiation to regulate erythrocyte size and number. Genes and Development, 2012, 26, 2075-2087.	2.7	100
121	The spectrum of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a description of 10 cases. Modern Pathology, 2012, 25, 661-674.	2.9	48
122	CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T-Cell Lymphomas. American Journal of Pathology, 2012, 181, 795-803.	1.9	52
123	Examination of Genetic Aberrations in <i>Chlamydomydia Psittaci</i> negative MALT Lymphomas of the Ocular Adnexa. Blood, 2012, 120, 1569-1569.	0.6	0
124	T-cell lymphomas: a tale of heterogeneity masking clarity. Leukemia and Lymphoma, 2011, 52, 1-2.	0.6	0
125	HGAL Protein Expression Persists in Disorders of Germinal Center Dissolution. Applied Immunohistochemistry and Molecular Morphology, 2011, 19, 266-272.	0.6	3
126	Clinicopathologic and Molecular Features of 122 Brazilian Cases of Nodal and Extranodal NK/T-Cell Lymphoma, Nasal Type, With EBV Subtyping Analysis. American Journal of Surgical Pathology, 2011, 35, 1195-1203.	2.1	119



#	ARTICLE	IF	CITATIONS
127	Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. <i>Blood</i> , 2011, 118, 1350-1358.	0.6	175
128	LMO2 protein expression predicts survival in patients with rheumatoid arthritis and diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1146-1149.	0.6	2
129	The Efficacy of HGAL and LMO2 in the Separation of Lymphomas Derived From Small B Cells in Nodal and Extranodal Sites, Including the Bone Marrow. <i>American Journal of Clinical Pathology</i> , 2011, 135, 697-708.	0.4	26
130	MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP. <i>Clinical Cancer Research</i> , 2011, 17, 4125-4135.	3.2	126
131	Evaluation of the Bone Marrow After Therapy. , 2011, , 918-938.		1
132	HGAL-a Germinal Center Specific Protein, Enhances B-Cell Receptor Signaling by Activation of Syk, Leading to Follicular Lymphoproliferation. <i>Blood</i> , 2011, 118, 584-584.	0.6	1
133	Processing of the Lymph Node Biopsy Specimen. , 2011, , 3-13.		1
134	Frontline Therapy of Nodular Lymphocyte Predominant Hodgkin Lymphoma with Rituximab: The Stanford University Experience. <i>Blood</i> , 2011, 118, 2686-2686.	0.6	3
135	Identification of LMO2 Transcriptome and Interactome in Diffuse Large B-Cell Lymphoma by Integrated Experimental and Computational Approach. <i>Blood</i> , 2011, 118, 438-438.	0.6	0
136	Immature T-Cell Populations in Lymph Nodes of Castleman Disease and Angioimmunoblastic T-Cell Lymphoma Suggest Alternate Sites of T-Cell Development,. <i>Blood</i> , 2011, 118, 3238-3238.	0.6	0
137	Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2011, 2, 245-52.	0.4	7
138	Immunoarchitectural Patterns in Follicular Lymphoma: Efficacy of HGAL and LMO2 in the Detection of the Interfollicular and Diffuse Components. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1266-1276.	2.1	40
139	The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation. <i>Haematologica</i> , 2010, 95, 432-439.	1.7	99
140	PD-1 Expression in T-cell Lymphomas and Reactive Lymphoid Entities: Potential Overlap in Staining Patterns Between Lymphoma and Viral Lymphadenitis. <i>American Journal of Surgical Pathology</i> , 2010, 34, 178-189.	2.1	71
141	Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). <i>British Journal of Haematology</i> , 2010, 148, 235-244.	1.2	38
142	Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 13069-13074.	3.3	79
143	Expression of LMO2 Is Associated With t(14;18)/IGH-BCL2 Fusion but Not BCL6 Translocations in Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2010, 134, 278-281.	0.4	8
144	C-C Chemokine Receptor 1 Expression in Human Hematolymphoid Neoplasia. <i>American Journal of Clinical Pathology</i> , 2010, 133, 473-483.	0.4	23

#	ARTICLE	IF	CITATIONS
145	Oral and Extraoral Plasmablastic Lymphoma. American Journal of Clinical Pathology, 2010, 134, 710-719.	0.4	74
146	Immunohistochemical Profiling of Lymphoma. , 2010, , 21-44.		0
147	CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. Human Pathology, 2010, 41, 271-280.	1.1	31
148	Programmed death 1 expression in variant immunoarchitectural patterns of nodular lymphocyte predominant Hodgkin lymphoma: comparison with CD57 and lymphomas in the differential diagnosis. Human Pathology, 2010, 41, 1726-1734.	1.1	40
149	Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. Modern Pathology, 2010, 23, 420-433.	2.9	39
150	Embryonic Stem Cellâ€œDerived Endothelial Cells Engraft Into the Ischemic Hindlimb and Restore Perfusion. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 984-991.	1.1	126
151	Building â€œTissueâ€•Microarrays from Suspension Cells. Methods in Molecular Biology, 2010, 664, 93-101.	0.4	6
152	Prognostic significance of CD15 expression in classical Hodgkin lymphoma (cHL): The Stanford University experience.. Journal of Clinical Oncology, 2010, 28, e18521-e18521.	0.8	1
153	Oral and extraoral plasmablastic lymphoma: Similarities and differences in clinicopathological characteristics.. Journal of Clinical Oncology, 2010, 28, e18539-e18539.	0.8	0
154	In Situ Vaccination with TLR9 Agonist Combined with Local Radiation In Mycosis Fungoides: Analysis of Phase I/II Study. Blood, 2010, 116, 286-286.	0.6	1
155	Clinical and Pathological Features of Non-Hodgkin Lymphomas Harboring Concurrent t(14;18) and 8q24 Anomalies. Blood, 2010, 116, 3134-3134.	0.6	0
156	Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment. Blood, 2010, 116, 2006-2006.	0.6	0
157	STAT3, Constitutively Activated In ABC-Like DLBCL, Regulates Expression of the Prognostic Factor Cyclin D2. Blood, 2010, 116, 705-705.	0.6	0
158	Immunoarchitectural Patterns in Nodal Marginal Zone B-Cell Lymphoma. American Journal of Clinical Pathology, 2009, 132, 39-49.	0.4	60
159	The Transcription Factor LMO2 Is a Robust Marker of Vascular Endothelium and Vascular Neoplasms and Selected Other Entities. American Journal of Clinical Pathology, 2009, 131, 264-278.	0.4	33
160	Characterization of c-Maf Transcription Factor in Normal and Neoplastic Hematolymphoid Tissue and Its Relevance in Plasma Cell Neoplasia. American Journal of Clinical Pathology, 2009, 132, 361-371.	0.4	14
161	Extracellular Signal-Regulated Kinase Positively Regulates the Oncogenic Activity of MCT-1 in Diffuse Large B-Cell Lymphoma. Cancer Research, 2009, 69, 7835-7843.	0.4	28
162	Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. Nature Medicine, 2009, 15, 566-571.	15.2	105

#	ARTICLE	IF	CITATIONS
163	Human germinal center-associated lymphoma protein expression is associated with improved failure-free survival in Brazilian patients with classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 1830-1836.	0.6	16
164	Lack of Utility of CD20 Immunohistochemistry in Staging Bone Marrow Biopsies for Diffuse Large B-cell Lymphoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2009, 17, 93-95.	0.6	4
165	Microtubule-associated Protein-2 is a Sensitive Marker of Primary and Metastatic Neuroblastoma. <i>American Journal of Surgical Pathology</i> , 2009, 33, 1695-1704.	2.1	19
166	Low Stage Follicular Lymphoma: Biologic and Clinical Characterization According to Nodal or Extranodal Primary Origin. <i>American Journal of Surgical Pathology</i> , 2009, 33, 591-598.	2.1	31
167	Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP). <i>Journal of Clinical Oncology</i> , 2009, 27, 8581-8581.	0.8	0
168	Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions.. <i>Blood</i> , 2009, 114, 622-622.	0.6	2
169	Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. <i>Laboratory Investigation</i> , 2008, 88, 38-47.	1.7	87
170	Expression of the human germinal-centre-associated lymphoma protein in diffuse large B-cell lymphomas in patients with rheumatoid arthritis. <i>British Journal of Haematology</i> , 2008, 141, 69-72.	1.2	21
171	Tissue Microarrays from Bone Marrow Aspirates for High-Throughput Assessment of Immunohistologic Markers in Pediatric Acute Leukemia. <i>Pediatric and Developmental Pathology</i> , 2008, 11, 283-290.	0.5	4
172	Immunohistochemical Characterization of Nasal-Type Extranodal NK/T-Cell Lymphoma Using a Tissue Microarray. <i>American Journal of Clinical Pathology</i> , 2008, 130, 343-351.	0.4	89
173	LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab. <i>Journal of Clinical Oncology</i> , 2008, 26, 447-454.	0.8	159
174	PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling. <i>Blood</i> , 2008, 112, 4098-4108.	0.6	118
175	Biological and clinical effects of single agent treatment with atorvastatin in patients with non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 8529-8529.	0.8	0
176	Closing the gap: A comparison of observed versus expected survival in follicular lymphoma (FL) at Stanford University from 1960-2003. <i>Journal of Clinical Oncology</i> , 2008, 26, 8535-8535.	0.8	0
177	LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy (RCHOP): A Multicenter Validation Study. <i>Blood</i> , 2008, 112, 3769-3769.	0.6	0
178	Expression of the RNA-binding protein VICKZ in normal hematopoietic tissues and neoplasms. <i>Haematologica</i> , 2007, 92, 176-183.	1.7	16
179	Expression of the human germinal center-associated lymphoma (HGAL) protein identifies a subset of classic Hodgkin lymphoma of germinal center derivation and improved survival. <i>Blood</i> , 2007, 109, 298-305.	0.6	45
180	The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. <i>Blood</i> , 2007, 109, 1636-1642.	0.6	139

#	ARTICLE	IF	CITATIONS
181	Oncogenic Regulators and Substrates of the Anaphase Promoting Complex/Cyclosome Are Frequently Overexpressed in Malignant Tumors. American Journal of Pathology, 2007, 170, 1793-1805.	1.9	92
182	Microvessel Density and Expression of Vascular Endothelial Growth Factor and Its Receptors in Diffuse Large B-Cell Lymphoma Subtypes. American Journal of Pathology, 2007, 170, 1362-1369.	1.9	76
183	The Biology of the Germinal Center. Hematology American Society of Hematology Education Program, 2007, 2007, 210-215.	0.9	30
184	The Stanford Tissue Microarray Database. Nucleic Acids Research, 2007, 36, D871-D877.	6.5	80
185	The utility of PAX5 immunohistochemistry in the diagnosis of undifferentiated malignant neoplasms. Modern Pathology, 2007, 20, 871-877.	2.9	32
186	Mast cell tryptase and microphthalmia transcription factor effectively discriminate cutaneous mast cell disease from myeloid leukemia cutis. Journal of Cutaneous Pathology, 2007, 34, 289-295.	0.7	14
187	The Biology of the Germinal Center. Hematology American Society of Hematology Education Program, 2007, 2007, 210-215.	0.9	4
188	Survival in Follicular Lymphoma: The Stanford Experience, 1960â€“2003.. Blood, 2007, 110, 3428-3428.	0.6	7
189	LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma in the Pre- and Post-Rituximab Treatment Eras.. Blood, 2007, 110, 52-52.	0.6	2
190	Prognostic Significance of VEGF, VEGF Receptors, and Microvessel Density in Diffuse Large B Cell Lymphoma Treated with Anthracycline-Based Chemotherapy.. Blood, 2007, 110, 53-53.	0.6	3
191	Transmembrane adaptor molecules: a new category of lymphoid-cell markers. Blood, 2006, 107, 213-221.	0.6	39
192	Loss of CD19 expression in B-cell neoplasms. Histopathology, 2006, 48, 239-246.	1.6	42
193	Bringing Pathobiology into Focus. Laboratory Investigation, 2006, 86, 632-632.	1.7	2
194	Prognostic immunohistologic markers in human tumors: why are so few used in clinical practice?. Laboratory Investigation, 2006, 86, 742-747.	1.7	19
195	CD10 expression in peripheral T-cell lymphomas complicated by a proliferation of large B-cells. Modern Pathology, 2006, 19, 337-343.	2.9	21
196	Low CD27 Expression in Plasma Cell Dyscrasias Correlates With High-Risk Disease. American Journal of Clinical Pathology, 2006, 126, 545-551.	0.4	20
197	EBV Can Protect Latently Infected B Cell Lymphomas from Death Receptor-Induced Apoptosis. Journal of Immunology, 2006, 177, 3283-3293.	0.4	45
198	Tissue Microarrays from Bone Marrow Aspirates for High Throughput Assessment of Immunohistologic Markers in Pediatric Acute Leukemia. Pediatric and Developmental Pathology, 2006, preprint, 1.	0.5	1

#	ARTICLE	IF	CITATIONS
199	The Oncoprotein LMO2 Is Expressed in a Germinal Center B-Cell-Associated Pattern and Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma.. Blood, 2006, 108, 810-810.	0.6	0
200	Expression of CD163 (Hemoglobin Scavenger Receptor) in Normal Tissues, Lymphomas, Carcinomas, and Sarcomas Is Largely Restricted to the Monocyte/Macrophage Lineage. American Journal of Surgical Pathology, 2005, 29, 617-624.	2.1	195
201	Follicular Dendritic Cell Immunohistochemical Markers in Angioimmunoblastic T-Cell Lymphoma. Applied Immunohistochemistry and Molecular Morphology, 2005, 13, 297-303.	0.6	20
202	Utility of Syndecan-1 (CD138) Expression in the Diagnosis of Undifferentiated Malignant Neoplasms. Applied Immunohistochemistry and Molecular Morphology, 2005, 13, 304-310.	0.6	55
203	A Novel Method for Making "Tissue" Microarrays From Small Numbers of Suspension Cells. Applied Immunohistochemistry and Molecular Morphology, 2005, 13, 80-84.	0.6	18
204	Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. Blood, 2005, 105, 3979-3986.	0.6	111
205	The NFATc1 transcription factor is widely expressed in white cells and translocates from the cytoplasm to the nucleus in a subset of human lymphomas. British Journal of Haematology, 2005, 128, 333-342.	1.2	69
206	TMA-Combiner, a simple software tool to permit analysis of replicate cores on tissue microarrays. Modern Pathology, 2005, 18, 1641-1648.	2.9	37
207	Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study. Journal of Cutaneous Pathology, 2005, 32, 227-234.	0.7	45
208	Cytologic diagnosis of Burkitt lymphoma. Cancer, 2005, 105, 310-318.	2.0	20
209	Expression of the Human Germinal Center Associated Lymphoma (HGAL) Protein Identifies a Subset of Classical Hodgkin Lymphoma of Germinal Center Derivation and Improved Outcome.. Blood, 2005, 106, 23-23.	0.6	0
210	RNA-Binding Protein VICKZ Is Expressed in a Germinal Center Associated Pattern among Lymphoma Subtypes.. Blood, 2005, 106, 1909-1909.	0.6	0
211	Atypical Cellular Disorders. Hematology American Society of Hematology Education Program, 2004, 2004, 283-296.	0.9	154
212	Intracellular signalling molecules as immunohistochemical markers of normal and neoplastic human leucocytes in routine biopsy samples. British Journal of Haematology, 2004, 124, 519-533.	1.2	23
213	Expression pattern of FCRL (FREB, FcRX) in normal and neoplastic human B cells. British Journal of Haematology, 2004, 127, 335-343.	1.2	30
214	Immunophenotypic and Genotypic Characterization of Progression in Follicular Lymphomas. Applied Immunohistochemistry and Molecular Morphology, 2004, 12, 97-104.	0.6	11
215	International Standardized Approach to Molecular and Flow Cytometric Residual Disease Monitoring in CLL.. Blood, 2004, 104, 15-15.	0.6	4
216	TNFRSF6 (Fas Antigen) Mutations in Patients with Sinus Histiocytosis with Massive Lymphadenopathy (Rosai-Dorfman Disease).. Blood, 2004, 104, 2389-2389.	0.6	3

#	ARTICLE	IF	CITATIONS
217	The Number of CD25+ Tumor-Infiltrating Cells May Predict Clinical Response to Rituximab in Follicular Lymphoma Patients.. Blood, 2004, 104, 748-748.	0.6	6
218	Expression of the Human Germinal Center-Associated Lymphoma (HGAL) Protein, a New Marker of Germinal Center B Cell Derivation.. Blood, 2004, 104, 2265-2265.	0.6	0
219	Expression of the B-Cell Proliferation Marker MUM1 by Melanocytic Lesions and Comparison with S100, gp100 (HMB45), and MelanA. Modern Pathology, 2003, 16, 802-810.	2.9	91
220	Characterization of Variant Patterns of Nodular Lymphocyte Predominant Hodgkin Lymphoma with Immunohistologic and Clinical Correlation. American Journal of Surgical Pathology, 2003, 27, 1346-1356.	2.1	311
221	Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood, 2003, 101, 4285-4289.	0.6	191
222	The Usefulness of Immunohistochemistry in the Diagnosis of Follicular Lymphoma in Bone Marrow Biopsy Specimens. American Journal of Clinical Pathology, 2002, 117, 636-643.	0.4	32
223	Chronic Myelogenous Leukemia Presenting as Extramedullary Lymphoid Blast Crisis. , 2002, 7, 117-123.		0
224	Chronic Myelogenous Leukemia Presenting as Extramedullary Lymphoid Blast Crisis. , 2002, 7, 117-123.		0
225	Software Tools for High-Throughput Analysis and Archiving of Immunohistochemistry Staining Data Obtained with Tissue Microarrays. American Journal of Pathology, 2002, 161, 1557-1565.	1.9	194
226	Apoptosis Stimulating Protein of p53 (ASPP2) Expression Differs in Diffuse Large B-cell and Follicular Center Lymphoma: Correlation with Clinical Outcome. Leukemia and Lymphoma, 2002, 43, 2309-2317.	0.6	47
227	Large atypical cells of lymphomatoid papulosis are CD56-negative: a study of 18 cases. Journal of Cutaneous Pathology, 2002, 29, 88-92.	0.7	26
228	Durable Remission in Recurrent T-Cellâ€”Rich B-Cell Lymphoma with the Anti-CD20 Antibody Rituximab. Clinical Lymphoma and Myeloma, 2001, 2, 185-187.	2.1	5
229	Analysis of MUM1/IRF4 Protein Expression Using Tissue Microarrays and Immunohistochemistry. Modern Pathology, 2001, 14, 686-694.	2.9	167
230	Modified Cyclophosphamide, Hydroxydaunorubicin, Vincristine, and Prednisone Therapy for Posttransplantation Lymphoproliferative Disease in Pediatric Patients Undergoing Solid Organ Transplantation. The American Journal of Pediatric Hematology/oncology, 2001, 23, 452-455.	1.3	18
231	Natural Killer/Natural Killer-Like T-Cell Lymphoma, CD56+, Presenting in the Skin: An Increasingly Recognized Entity With an Aggressive Course. Journal of Clinical Oncology, 2001, 19, 2179-2188.	0.8	153
232	Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood, 2001, 98, 945-951.	0.6	272
233	Natural Killer Cell Precursor Acute Lymphoma/Leukemia Presenting in an Infant. Archives of Pathology and Laboratory Medicine, 2001, 125, 413-418.	1.2	9
234	Blastic/Blastoid Transformation of Follicular Lymphoma. American Journal of Surgical Pathology, 2000, 24, 525-534.	2.1	45

#	ARTICLE	IF	CITATIONS
235	Utility of Paraffin Section Immunohistochemistry for C-KIT (CD117) in the Differential Diagnosis of Systemic Mast Cell Disease Involving the Bone Marrow. American Journal of Surgical Pathology, 2000, 24, 81.	2.1	49
236	Co-expression of CD56 and CD30 in lymphomas with primary presentation in the skin: clinicopathologic, immunohistochemical and molecular analyses of seven cases. Journal of Cutaneous Pathology, 2000, 27, 392-399.	0.7	45
237	Immunoblot Analysis of CD34 Expression in Histologically Diverse Neoplasms. American Journal of Pathology, 2000, 156, 21-27.	1.9	64
238	Aggressive Natural Killer-Like T-Cell Malignancy With Leukemic Presentation Following Solid Organ Transplantation. American Journal of Clinical Pathology, 1999, 111, 663-671.	0.4	21
239	Aggressive Cutaneous NK and NK-like T-Cell Lymphomas. American Journal of Surgical Pathology, 1999, 23, 571-581.	2.1	107
240	Epstein-Barr virus strain type and latent membrane protein 1 gene deletions in lymphomas in patients with rheumatic diseases. Arthritis and Rheumatism, 1997, 40, 1152-1156.	6.7	13
241	Nuclear signaling by interleukin-6. Current Opinion in Immunology, 1993, 5, 124-128.	2.4	45
242	Acute Leukemia. , 0, , 70-89.		0
243	Large Granular Lymphocyte Leukemia. , 0, , 165-167.		0
244	Lymphoplasmacytic Lymphoma (Including Waldenström Macroglobulinemia). , 0, , 116-121.		0
245	Mantle Cell Lymphoma. , 0, , 122-125.		0
246	Follicular Lymphoma. , 0, , 126-131.		0
247	Marginal Zone B Cell Lymphoma (Including Malt Type). , 0, , 132-134.		0
248	Hairy Cell Leukemia. , 0, , 135-141.		0
249	Diffuse Large B Cell Lymphoma. , 0, , 153-158.		0
250	Burkitt Lymphoma. , 0, , 159-164.		0
251	The Normal Bone Marrow. , 0, , 5-19.		0
252	Cutaneous T Cell Lymphoma. , 0, , 168-169.		0



#	ARTICLE	IF	CITATIONS
253	Peripheral T Cell Lymphomas, Unspecified. , 0, , 170-172.		0
254	Hepatosplenic T Cell Lymphoma. , 0, , 173-174.		0
255	Angioimmunoblastic T Cell Lymphoma. , 0, , 175-177.		0
256	Adult T Cell Lymphoma/Leukemia. , 0, , 178-179.		0
257	Anaplastic Large Cell Lymphoma. , 0, , 180-182.		0
258	Metastatic Disease. , 0, , 190-196.		0
259	Technical Considerations. , 0, , 209-213.		34
260	Human Immunodeficiency Virus Infection. , 0, , 20-30.		0
261	Anemias and Aplasias. , 0, , 31-40.		0
262	The Myelodysplastic Syndromes. , 0, , 41-47.		0
263	Myeloproliferative Disease. , 0, , 48-69.		0
264	Lymphomas. , 0, , 90-101.		0
265	Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. , 0, , 102-108.		0